Skip NavigationSkip to Content
Return Return to Search Results

Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate

  1. Author:
    Earl, P. L.
    Americo, J. L.
    Wyatt, L. S.
    Eller, L. A.
    Montefiori, D. C.
    Byrum, R.
    Piatak, M.
    Lifson, J. D.
    Amara, R. R.
    Robinson, H. L.
    Huggins, J. W.
    Moss, B.

  2. Author Address

    Natl Inst Hlth, NIAID, Viral Dis Lab, Bethesda, MD 20892 USA. Henry M Jackson Fdn, Rockville, MD 20852 USA. Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA. Bioqual, Rockville, MD 20850 USA. Natl Canc Inst, AIDS Vaccine Program, Sci Appl Int Corp, Ft Detrick, MD 21702 USA. Emory Univ, Yerkes Natl Primate Res Ctr, Vaccine Res Ctr, Dept Microbiol Immunol, Atlanta, GA 30329 USA. USA, Med Res Inst Infect Dis, Ft Detrick, MD 21702 USA.;Earl, PL, Natl Inst Hlth, NIAID, Viral Dis Lab, Bldg 33,Room 1E19,33 N Dr, Bethesda, MD 20892 USA.;pearl@niaid.nih.gov
    1. Year: 2007
    2. Date: Sep
  2. Journal: Virology
    1. 366
    2. 1
    3. Pages: 84-97
  4. Type of Article: Article
  5. ISSN: 0042-6822
  1. Abstract:

    Recombinant and non-recombinant modified vaccinia virus Ankara (MVA) strains are currently in clinical trials as human immunodeficiency virus-1 (HIV) and attenuated smallpox vaccines, respectively. Here we tested the ability of a recombinant MVA delivered by alternative needlefree routes (intramuscular, intradennal, or into the palatine tonsil) to protect against immunodeficiency and orthopoxvirus diseases in a non-human primate model. Rhesus macaques were immunized twice I month apart with MVA expressing 5 genes from a pathogenic simian human immunodeficiency virus (SHIV)/89.6P and challenged intrarectally 9 months later with the pathogenic SHIV/89.6P and intravenously 2.7 years later with monkeypox virus. Irrespective of the route of vaccine delivery, binding and neutralizing antibodies and CD8 responses to SHIV and orthopoxvirus proteins were induced and the monkeys were successively protected against the diseases caused by the challenge viruses in unimmunized controls as determined by viral loads and clinical signs. These non-human primate studies support the clinical testing of recombinant MVA as an HIV vaccine and further demonstrate that MVA can provide long-term poxvirus immunity, essential for use as an alternative smallpox vaccine. (c) 2007 Elsevier Inc. All rights reserved.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.virol.2007.02.041
  3. View record in Web of Science®
  4. WOS: 000249414900010

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel